Jean Bousquet1, Eli O Meltzer2, Peter Couroux3, Arkady Koltun4, Ferdinand Kopietz5, Ullrich Munzel5, Hans Christian Kuhl5, Duc Tung Nguyen5, Anne Marie Salapatek2, David Price6. 1. MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France; INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines; Euforea, Brussels, Belgium; Charité, Berlin, Germany. Electronic address: jean.bousquet@orange.fr. 2. Allergy and Asthma Medical Group and Research Center, San Diego, Calif. 3. Inflamax Research, Mississaugua, Ontario, Canada. 4. Mylan, Canonsburg, Pa. 5. Meda Pharma GmbH & Co. KG (a Mylan Company), Bad Homurg, Germany. 6. Observational and Pragmatic Research Institute, Singapore; Optimum Patient Care, Cambridge, UK; Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK.
Abstract
BACKGROUND: A fixed-dose combination of intranasal azelastine hydrochloride and fluticasone propionate (MP-AzeFlu) is the most effective treatment of allergic rhinitis, but its onset of action requires further investigation. OBJECTIVE: To compare the onset of action of MP-AzeFlu with the free combination of oral loratadine (LORA) and intranasal fluticasone propionate (INFP). METHODS: In this single-center, randomized, placebo-controlled, double-blind, double-dummy, 3-period crossover trial, allergic rhinitis symptoms were induced in asymptomatic patients by ragweed pollen challenge in an allergen environmental exposure chamber. Patients received single-dose MP-AzeFlu, LORA/INFP, or placebo and were monitored for 4 hours. The primary outcome was onset of action measured by total nasal symptom score (TNSS). Secondary measures were total ocular symptom score (TOSS), total score of the 7 nasal and ocular symptoms (T7SS), and the global visual analog scale (VAS). RESULTS: The full analysis set included 82 patients, of which 78 completed all treatments. TNSS was significantly reduced versus placebo from 5 minutes for MP-AzeFlu and 150 minutes for LORA/INFP onward (both P < .05) till the end of assessment (0-4 hours). MP-AzeFlu reduced TNSS to a greater extent at each time point from 5 to 90 minutes (P < .05) and over the entire assessment interval (P ≤ .005) versus LORA/INFP or placebo. No statistically significant difference between LORA/INFP and placebo was observed over the assessment interval (P = .182). The onset of action of MP-AzeFlu assessed by TOSS, T7SS, and VAS was 10 minutes, 2 hours earlier than with LORA/INFP. CONCLUSION: MP-AzeFlu had a more rapid onset of action (5 minutes) and was more effective than LORA/INFP.
RCT Entities:
BACKGROUND: A fixed-dose combination of intranasal azelastine hydrochloride and fluticasone propionate (MP-AzeFlu) is the most effective treatment of allergic rhinitis, but its onset of action requires further investigation. OBJECTIVE: To compare the onset of action of MP-AzeFlu with the free combination of oral loratadine (LORA) and intranasal fluticasone propionate (INFP). METHODS: In this single-center, randomized, placebo-controlled, double-blind, double-dummy, 3-period crossover trial, allergic rhinitis symptoms were induced in asymptomatic patients by ragweed pollen challenge in an allergen environmental exposure chamber. Patients received single-dose MP-AzeFlu, LORA/INFP, or placebo and were monitored for 4 hours. The primary outcome was onset of action measured by total nasal symptom score (TNSS). Secondary measures were total ocular symptom score (TOSS), total score of the 7 nasal and ocular symptoms (T7SS), and the global visual analog scale (VAS). RESULTS: The full analysis set included 82 patients, of which 78 completed all treatments. TNSS was significantly reduced versus placebo from 5 minutes for MP-AzeFlu and 150 minutes for LORA/INFP onward (both P < .05) till the end of assessment (0-4 hours). MP-AzeFlu reduced TNSS to a greater extent at each time point from 5 to 90 minutes (P < .05) and over the entire assessment interval (P ≤ .005) versus LORA/INFP or placebo. No statistically significant difference between LORA/INFP and placebo was observed over the assessment interval (P = .182). The onset of action of MP-AzeFlu assessed by TOSS, T7SS, and VAS was 10 minutes, 2 hours earlier than with LORA/INFP. CONCLUSION:MP-AzeFlu had a more rapid onset of action (5 minutes) and was more effective than LORA/INFP.
Authors: Ayşe Arzu Yorgancıoğlu; Bilun Gemicioğlu; Cemal Cingi; Ömer Kalaycı; Ali Fuat Kalyoncu; Claus Bachert; Peter Hellings; Oliver Pfaar; Holger J Schünemann; Dana Wallace; Anna Bedbrook; Wienczyslawa Czarlewski; Jean Bousquet Journal: Turk Thorac J Date: 2020-03-01
Authors: J Bousquet; A Bedbrook; W Czarlewski; G L Onorato; S Arnavielhe; D Laune; E Mathieu-Dupas; J Fonseca; E Costa; O Lourenço; M Morais-Almeida; A Todo-Bom; M Illario; E Menditto; G W Canonica; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; W J Fokkens; N H Chavannes; S Reitsma; A A Cruz; J da Silva; F S Serpa; D Larenas-Linnemann; J M Fuentes Perez; Y R Huerta-Villalobos; D Rivero-Yeverino; E Rodriguez-Zagal; A Valiulis; R Dubakiene; R Emuzyte; V Kvedariene; I Annesi-Maesano; H Blain; P Bonniaud; I Bosse; Y Dauvilliers; P Devillier; J F Fontaine; J L Pépin; N Pham-Thi; F Portejoie; R Picard; N Roche; C Rolland; P Schmidt-Grendelmeier; P Kuna; B Samolinski; J M Anto; V Cardona; J Mullol; H Pinnock; D Ryan; A Sheikh; S Walker; S Williams; S Becker; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P V Tomazic; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; T Vasankari; B Gemicioğlu; A Yorgancioglu; N G Papadopoulos; E P Prokopakis; I G Tsiligianni; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; M E Zernotti; I Kull; E Melén; M Wickman; C Bachert; P W Hellings; G Brusselle; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; L P Boulet; J Bouchard; D K Chu; H J Schünemann; M Sova; G De Vries; M van Eerd; I Agache; I J Ansotegui; M Bewick; T Casale; M Dykewick; M Ebisawa; R Murray; R Naclerio; Y Okamoto; D V Wallace Journal: Clin Transl Allergy Date: 2019-03-11 Impact factor: 5.871
Authors: Petra Zieglmayer; René Schmutz; Patrick Lemell; Nicole Unger-Manhart; Sabine Nakowitsch; Andreas Goessl; Markus Savli; René Zieglmayer; Eva Prieschl-Grassauer Journal: Clin Exp Allergy Date: 2020-07-07 Impact factor: 5.018
Authors: Hilda J I De Jong; Jaco Voorham; Glenis K Scadding; Claus Bachert; Giorgio Walter Canonica; Peter Smith; Ulrich Wahn; Dermot Ryan; Jose A Castillo; Victoria A Carter; Ruth B Murray; David B Price Journal: World Allergy Organ J Date: 2020-12-19 Impact factor: 4.084
Authors: William E Berger; Claus Bachert; Robert Allara; Arkady Koltun; Ferdinand Kopietz; Joachim G Maus; Alexander D D'Addio Journal: J Asthma Allergy Date: 2020-05-28